Skip to main content

Table 1 Characteristics of patients in the included studies

From: Effect of stem cell transplantation on patients with ischemic heart failure: a systematic review and meta-analysis of randomized controlled trials

Author, year Number Cell type Cell dose Course of treatment (months)
Amit N Patel, 2016 [24] 66 Ixmyelocel-T+BMA 0.8 ml 12
60 Placebo+BMA 0.8 ml 12
Amit N. Patel, 2005 [11] 10 Stem cells (CD34+) 250 ml 6
10 Own plasma 30 ml 6
Amit N. Patel, 2015 [12] 24 BMAC infusion 240 ml 12
6 Medical standard of care 12
Anders Bruun Mathiasen, 2015 [13] 40 MSCs 0.2 ml 6
20 PBS 0.2 ml 6
Emerson C. Perin, 2011 [6] 20 ABMMNC 3 ml 6
10 Simulated mock injection 6
Emerson C. Perin, 2012 [2] 10 ALDHbr 3 ml 6
10 5% Albumin 3 ml 6
Emerson C. Perin, 2003 [7] 14 ABMMNC 50 ml 2
7 Placebo 4
Jozef Bartunek, 2013 [3] 32 Bone marrow stem cells 50 × 106 24
15 Standard of care 24
Shengshou Hu, 2011 [8] 31 CABG+BMMNC 60 ml 6
29 CABG 10 ml 6
Zhi Qi, 2015 [25] 24 CABG+BMMNC 60 ml 12
18 CABG 10 ml 12
Evgeny Pokushalov, 2010 [26] 49 ABMMNC+Medical therapy 41 ± 16 × 106 12
31 Medical therapy  
Nabil Dib, 2009 [27] 12 AMT+MMT 2.5 × 107 12
11 MMT  
Philippe Menasché, 2008 [29] 30 Myoblast 8 × 108 6
34 Placebo  
Qiang Zhao, 2008 [28] 18 BMMNC An average of 6.59 × 108 ± 5.12 × 108 6
18 Saline  
  1. BMA bone marrow aspirate, BMAC bone marrow aspirate concentrate, MSCs mesenchymal stromal cells, PBS phosphate buffer saline, BMC bone marrow cell, ABMMNC autologous bone marrow mononuclear cell, ALDHbr aldehyde dehydrogenase-bright, MPCs mesenchymal precursor cells, CABG coronary artery bypass graft, BMMNC bone marrow mononuclear cell, AMT autologous myoblast transplant, MMT maximal medical therapy